Research News
Macular Degeneration Research grantees are looking at new ways to stop age-related macular degeneration. Two, in particular, are hoping that vitamins and diet will provide solutions.
Top U.S. scientists are concerned that eye and vision health are relatively absent from national health priority lists. AMD, in particular, is rising..
Download the fall edition of our macular degeneration research newsletter and read about new treatments that are on the horizon, the latest research grants awarded for pioneering macular degeneration research, the first-ever bionic eye for patients with macular degeneration, and more.
In a major scientific breakthrough, a drug used to treat Parkinson’s and related diseases may be able to delay or prevent age-related macular degeneration (AMD), the most common form of blindness among older Americans.
Download the summer 2015 issue of our macular degeneration newsletter to learn about a new AMD treatment that is close to human clinical trials, how cataract surgery affects AMD, AREDS vitamins. risk reduction strategies for AMD, and more.
BrightFocus Foundation seeks to save sight and mind by funding innovative research worldwide and by promoting better health through education.
In an online report published April 2, 2014, BrightFocus researchers Matthew Campbell, PhD, Sarah Doyle, PhD, and Peter Humphries, PhD, and their teams, have reported from studies in mice that the inflammatory cytokine interleukin-18 (IL-18) can prevent choroidal neovascularization (CNV) formation—the fragile, leaky blood vessels forming on the retina that are the hallmark of wet AMD—and is not toxic to the retinal pigment epithelium.
